Novel 175Yb-Poly (L-lactic acid) microspheres for transarterial radioembolization of unrespectable hepatocellular carcinoma

Authors

  • mina jamre Faculty of Energy Engineering and Physics, Amirkabir University of Technology, Tehran, Iran
  • mohammad ghannadi-maraghe Radiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran.
  • Mojtaba Shamsaei Faculty of Energy Engineering and Physics, Amirkabir University of Technology, Tehran, Iran.
  • Sodeh Sadjadi Material and Nuclear Fuel Cycle School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran.
Abstract:

Novel biodegradable Poly (L-lactic acid) (PLLA) microspheres containing ytterbium were designed for intra-tumoral radiotherapy, especially for radioembolization. 175Yb possess both therapeutic beta and diagnostic gamma radiations. In this work, process to make ready radiomicrospheres 175Yb(acac)3-loaded PLLA for more consideration has been investigated. The radiomicrospheres were prepared with approximate size of 20-40 µm, and radionuclidic purity > 92%. The radiomicrospheres were stable in vitro for up to 72 h in normal saline, and also in human serum albumin (HSA). Biodistribution in mice bearing 4T1 tumor showed specific radionuclide uptake over 48 h. Tumor necrosis was also observed at the injection site up to 12 days after injection. These data showed that 175Yb-PLLA microspheres could be prepared and considered further for radiomicrospheres tumor therapy.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Neutron activation of holmium poly(L-lactic acid) microspheres for hepatic arterial radioembolization: a validation study

Poly(L-lactic acid) microspheres loaded with holmium-166 acetylacetonate (166Ho-PLLA-MS) are a novel microdevice for intra-arterial radio-embolization in patients with unresectable liver malignancies. The neutron activation in a nuclear reactor, in particular the gamma heating, damages the 166Ho-PLLA-MS. The degree of damage is dependent on the irradiation characteristics and irradiation time i...

full text

Transarterial radioembolization for hepatocellular carcinoma: a review

Hepatocellular carcinoma (HCC) is the most common type of liver cancer and is the second cause of death due to malignancy in the world. The treatment of HCC is complex and includes potentially curative and palliative approaches. However, both curative and palliative treatments for HCC are often associated with a not-completely favorable safety/efficacy ratio. Therefore, other treatment options ...

full text

Locoregional Transarterial Therapies for Hepatocellular Carcinoma: Transarterial Chemoembolization and Radioembolization

Background: Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world and the third most common cause of cancer-related mortality. Despite the widespread implementation of surveillance programs, more than half of the patients with HCC are diagnosed at late stages, when curative treatments (resection or liver transplantation) cannot be applied. For patients presenting with unre...

full text

Transarterial radioembolization for hepatocellular carcinoma: An update and perspectives.

In the last decade trans-arterial radioembolization has given promising results in the treatment of patients with intermediate or advanced stage hepatocellular carcinoma (HCC), both in terms of disease control and tolerability profile. This technique consists of the selective intra-arterial administration of microspheres loaded with a radioactive compound (usually Yttrium(90)), and exerts its t...

full text

Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments

A selective intra-arterial liver injection using yttrium-90-loaded microspheres as sources for internal radiation therapy is a form of transarterial radioembolization (TARE). Current data from the literature suggest that TARE is effective in hepatocellular carcinoma (HCC) and is associated with a low rate of adverse events; however, they are all based on retrospective series or non-controlled p...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 18  issue 2

pages  569- 578

publication date 2019-05-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023